Peregrine Capital Management LLC Purchases 140,370 Shares of ADMA Biologics Inc $ADMA

Peregrine Capital Management LLC increased its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 29.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 611,826 shares of the biotechnology company’s stock after purchasing an additional 140,370 shares during the quarter. Peregrine Capital Management LLC’s holdings in ADMA Biologics were worth $5,513,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ADMA. Boothbay Fund Management LLC acquired a new position in ADMA Biologics in the 3rd quarter valued at $11,334,000. Tealwood Asset Management Inc. acquired a new stake in shares of ADMA Biologics during the fourth quarter worth $1,315,000. American Century Companies Inc. lifted its holdings in shares of ADMA Biologics by 1.8% during the third quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock worth $68,842,000 after buying an additional 84,934 shares in the last quarter. First Light Asset Management LLC boosted its position in shares of ADMA Biologics by 12.3% in the third quarter. First Light Asset Management LLC now owns 1,069,233 shares of the biotechnology company’s stock valued at $15,675,000 after acquiring an additional 117,137 shares during the period. Finally, B Group Inc. boosted its position in shares of ADMA Biologics by 4.1% in the third quarter. B Group Inc. now owns 2,412,542 shares of the biotechnology company’s stock valued at $35,368,000 after acquiring an additional 95,000 shares during the period. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Price Performance

ADMA stock opened at $8.61 on Thursday. The company’s 50-day moving average price is $8.78 and its two-hundred day moving average price is $13.11. The firm has a market cap of $2.00 billion, a P/E ratio of 12.66 and a beta of 0.72. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.19. The business had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The firm’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter last year, the business posted $0.11 EPS. On average, analysts anticipate that ADMA Biologics Inc will post 0.82 earnings per share for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman bought 12,500 shares of ADMA Biologics stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the acquisition, the director owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ADMA. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Mizuho lowered their target price on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Zacks Research downgraded shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 26th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $19.67.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: The company’s own financial backdrop is not weak: ADMA previously reported EPS in line with expectations and posted strong profitability metrics, which could help support investor confidence if legal issues are resolved.
• Neutral Sentiment: Multiple law firms announced August 10, 2026 lead-plaintiff deadlines and encouraged affected investors to join or lead the class action, keeping the lawsuit in the spotlight but adding no new business fundamentals. Article Title
• Neutral Sentiment: Lowey Dannenberg and other firms said they are investigating ADMA for possible federal securities law violations, extending the legal uncertainty around the stock. Article Title
• Negative Sentiment: A new securities-fraud class action alleges ADMA made misleading statements about revenues and internal controls during the August 2024 to March 2026 period, raising the risk of damages, legal costs, and further headline risk. Article Title
• Negative Sentiment: Earlier allegations that ADMA concealed channel stuffing and an undisclosed related-party distributor continue to drive the stock’s legal overhang and may keep shares volatile. Article Title

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.